Nivolumab for advanced non-small cell lung cancer: an immunologically-mediated tumor checkout

Non-small cell lung cancer (NSCLC) is associated with high mortality especially in the most advanced stages and when tumor is not responsive to the first line, conventional platinum-based chemotherapy or to newer compounds such as pemetrexed or erlotinib. Therefore newer agents with different mechanisms of action are needed and nivolumab is a relevant example of the kind.